Teva Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TEVA PHARMS, and when can generic versions of TEVA PHARMS drugs launch?
TEVA PHARMS has three hundred and nineteen approved drugs.
There are two US patents protecting TEVA PHARMS drugs. There are forty-four tentative approvals on TEVA PHARMS drugs.
There are seventeen patent family members on TEVA PHARMS drugs in twelve countries and nine hundred and thirty-six supplementary protection certificates in eighteen countries.
Summary for Teva Pharms
International Patents: | 17 |
US Patents: | 2 |
Tradenames: | 265 |
Ingredients: | 260 |
NDAs: | 319 |
Drugs and US Patents for Teva Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Pharms Usa | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 202491-001 | Nov 3, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Pharms | OLANZAPINE | olanzapine | TABLET;ORAL | 076000-002 | Oct 24, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Teva Pharms | DOXEPIN HYDROCHLORIDE | doxepin hydrochloride | CREAM;TOPICAL | 215408-001 | Feb 17, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Pharms Usa | ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 208432-001 | Oct 31, 2018 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Teva Pharms Usa | ALYQ | tadalafil | TABLET;ORAL | 209942-001 | Feb 5, 2019 | AB2 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,362,161 | ⤷ Sign Up |
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-002 | Feb 12, 2002 | 6,620,847 | ⤷ Sign Up |
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-001 | Feb 1, 2007 | 9,375,410 | ⤷ Sign Up |
Teva Pharms Intl | AMRIX | cyclobenzaprine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021777-002 | Feb 1, 2007 | 9,375,410 | ⤷ Sign Up |
Teva Pharms Usa | COPAXONE | glatiramer acetate | FOR SOLUTION;SUBCUTANEOUS | 020622-001 | Dec 20, 1996 | 6,620,847 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
Premature patent expirations for TEVA PHARMS
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
⤷ Sign Up | ⤷ Sign Up |
International Patents for Teva Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 2177223 | ⤷ Sign Up |
European Patent Office | 1443933 | ⤷ Sign Up |
Spain | 2334774 | ⤷ Sign Up |
Japan | 4794816 | ⤷ Sign Up |
Portugal | 1443933 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1632232 | SPC/GB17/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF RILPIVIRINE HYDROCHLORIDE, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE.; REGISTERED: UK EU/1/16/1112 (NI) 20160623; UK PLGB 11972/0019 20160623 |
1412357 | 122008000046 | Germany | ⤷ Sign Up | PRODUCT NAME: SITAGLIPTIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE SITAGLIPTINPHOSPHAT- MONOHYDRAT, IN KOMBINATION MIT METFORMIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 FIRST REGISTRATION: CH/LI 58450 01 58450 02 58450 03 20080408 |
2101777 | 2016C/032 | Belgium | ⤷ Sign Up | PRODUCT NAME: AMBRISENTAN EN COMBINAISON AVEC LE TADALAFIL; AUTHORISATION NUMBER AND DATE: EU/1/08/451 20151125 |
2435025 | LUC00124 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, ENANTIOMERES OU AUTRES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
0367141 | SPC/GB04/039 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: ARIPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/04/276/001 20040604; UK EU/1/04/276/002 20040604; UK EU/1/04/276/003 20040604; UK EU/1/04/276/004 20040604; UK EU/1/04/276/005 20040604; UK EU/1/04/276/006 20040604; UK EU/1/04/276/007 20040604; UK EU/1/04/276/008 20040604; UK EU/1/04/276/009 20040604; UK EU/1/04/276/010 20040604; UK EU/1/04/276/011 20040604; UK EU/1/04/276/012 20040604; UK EU/1/04/276/013 20040604; UK EU/1/04/276/014 20040604; UK EU/1/04/276/015 20040604; UK EU/1/04/276/016 20040604; UK EU/1/04/276/017 20040604; UK EU/1/04/276/018 20040604; UK EU/1/04/276/019 20040604; UK EU/1/04/276/020 20040604 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.